Bremelanotide · Melanocortin Receptor Agonist
Melanocortin-4 receptor agonist. Studied in CNS-mediated pathway research.
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II. Unlike PDE5 inhibitors, it acts centrally through MC3R and MC4R receptors in the CNS to modulate sexual behavior pathways. It received FDA approval (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women, providing clinical validation for its CNS-mediated mechanism.
Store lyophilized at -20°C. Reconstituted: 2–8°C, use within 4–6 weeks. Kit only.